Serine protease inhibitor 6 plays a critical role in protecting murine granzyme B-producing regulatory T cells

Journal of Immunology

Volumn 191, Issue 5, 2013, Pages 2319-2327

  Azzi, Jamil ^a   Skartsis, Nikolaos ^a   Mounayar, Marwan ^a   Magee, Ciara N ^a   Batal, Ibrahim ^a   Ting, Christopher ^a   Moore, Robert ^a   Riella, Leonardo V ^a   Ohori, Shunsuke ^a   Abdoli, Rozita ^a   Smith, Brian ^a   Fiorina, Paolo ^a   Heathcote, Dean ^b   Bakhos, Tannous ^c   Ashton Rickardt, Philip G ^b   Abdi, Reza ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; SERINE PROTEASE INHIBITOR 6; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LOCALIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MOLECULAR DYNAMICS; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; WILD TYPE;

ANIMALS; APOPTOSIS; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; GRANZYMES; HEART TRANSPLANTATION; HOMEOSTASIS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; SERINE ENDOPEPTIDASES; SERPINS; T-LYMPHOCYTES, REGULATORY;

EID: 84883386689     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300851     Document Type: Article

References (30)

1. Wood, K. J., and S. Sakaguchi. 2003. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3: 199-210.
2. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133: 775-787.
3. Webster, K. E., S. Walters, R. E. Kohler, T. Mrkvan, O. Boyman, C. D. Surh, S. T. Grey, and J. Sprent. 2009. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J. Exp. Med. 206: 751-760.
4. Raimondi, G., T. L. Sumpter, B. M. Matta, M. Pillai, N. Corbitt, Y. Vodovotz, Z. Wang, and A. W. Thomson. 2010. Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients. J. Immunol. 184: 624-636.
5. Trzonkowski, P., M. Bieniaszewska, J. Júscínska, A. Dobyszuk, A. Krzystyniak, N. Marek, J. Mýsliwska, and A. Hellmann. 2009. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin. Immunol. 133: 22-26.
6. Collison, L. W., C. J. Workman, T. T. Kuo, K. Boyd, Y. Wang, K. M. Vignali, R. Cross, D. Sehy, R. S. Blumberg, and D. A. Vignali. 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566-569.
7. Pandiyan, P., L. Zheng, S. Ishihara, J. Reed, and M. J. Lenardo. 2007. CD4 +CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat. Immunol. 8: 1353-1362.
8. Campbell, D. J., and S. F. Ziegler. 2007. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat. Rev. Immunol. 7: 305-310.
9. Riley, J. L., C. H. June, and B. R. Blazar. 2009. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity 30: 656-665.
10. Shevach, E. M. 2009. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30: 636-645.
11. Gondek, D. C., V. Devries, E. C. Nowak, L. F. Lu, K. A. Bennett, Z. A. Scott, and R. J. Noelle. 2008. Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells. J. Immunol. 181: 4752-4760.
12. Gondek, D. C., L. F. Lu, S. A. Quezada, S. Sakaguchi, and R. J. Noelle. 2005. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J. Immunol. 174: 1783-1786.
13. Cao, X., S. F. Cai, T. A. Fehniger, J. Song, L. I. Collins, D. R. Piwnica-Worms, and T. J. Ley. 2007. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27: 635-646.
14. Lovo, E., M. Zhang, L. Wang, and P. G. Ashton-Rickardt. 2012. Serine protease inhibitor 6 is required to protect dendritic cells from the kiss of death. J. Immunol. 188: 1057-1063.
15. Zhang, M., S. M. Park, Y. Wang, R. Shah, N. Liu, A. E. Murmann, C. R. Wang, M. E. Peter, and P. G. Ashton-Rickardt. 2006. Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity 24: 451-461.
16. Trapani, J. A., and M. J. Smyth. 2002. Functional significance of the perforin/granzyme cell death pathway. Nat. Rev. Immunol. 2: 735-747.
17. Liu, N., S. M. Raja, F. Zazzeroni, S. S. Metkar, R. Shah, M. Zhang, Y. Wang, D. Brömme, W. A. Russin, J. C. Lee, et al. 2003. NF-kappaB protects from the lysosomal pathway of cell death. EMBO J. 22: 5313-5322.
18. Corry, A. M. 1973. 1973 meeting in kansas city. Bull. Med. Libr. Assoc. 61: 39-43.
19. Stewart, S., G. L. Winters, M. C. Fishbein, H. D. Tazelaar, J. Kobashigawa, J. Abrams, C. B. Andersen, A. Angelini, G. J. Berry, M. M. Burke, et al. 2005. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J. Heart Lung Transplant. 24: 1710-1720.
20. Ansari, A. W., J. N. Temblay, S. H. Alyahya, and P. G. Ashton-Rickardt. 2010. Serine protease inhibitor 6 protects iNKT cells from self-inflicted damage. J. Immunol. 185: 877-883.
21. Scholzen, T., and J. Gerdes. 2000. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 182: 311-322.
22. Tannous, B. A. 2009. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat. Protoc. 4: 582-591.
23. Wurdinger, T., C. Badr, L. Pike, R. de Kleine, R. Weissleder, X. O. Breakefield, and B. A. Tannous. 2008. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat. Methods 5: 171-173.
24. Schenk, S., D. D. Kish, C. He, T. El-Sawy, E. Chiffoleau, C. Chen, Z. Wu, S. Sandner, A. V. Gorbachev, K. Fukamachi, et al. 2005. Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+ CD25+ T cells. J. Immunol. 174: 3741-3748.
25. Tarasenko, T., H. K. Kole, A. W. Chi, M. M. Mentink-Kane, T. A. Wynn, and S. Bolland. 2007. T cell-specific deletion of the inositol phosphatase SHIP reveals its role in regulating Th1/Th2 and cytotoxic responses. Proc. Natl. Acad. Sci. USA 104: 11382-11387.
26. Yang, J., L. V. Riella, O. Boenisch, J. Popoola, S. Robles, T. Watanabe, V. Vanguri, X. Yuan, I. Guleria, L. A. Turka, et al. 2009. Paradoxical functions of B7: CD28 costimulation in a MHC class II-mismatched cardiac transplant model. Am. J. Transplant. 9: 2837-2844.
27. Ashton-Rickardt, P. G. 2010. Serine protease inhibitors and cytotoxic T lymphocytes. Immunol. Rev. 235: 147-158.
28. Cai, S. F., X. Cao, A. Hassan, T. A. Fehniger, and T. J. Ley. 2010. Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. Blood 115: 1669-1677.
29. Young, J. L., G. K. Sukhova, D. Foster, W. Kisiel, P. Libby, and U. Schönbeck. 2000. The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. J. Exp. Med. 191: 1535-1544.
30. Annand, R. R., J. R. Dahlen, C. A. Sprecher, P. De Dreu, D. C. Foster, J. A. Mankovich, R. V. Talanian, W. Kisiel, and D. A. Giegel. 1999. Caspase-1 (interleukin-1beta-converting enzyme) is inhibited by the human serpin analogue proteinase inhibitor 9. Biochem. J. 342: 655-665.